Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00743431
First received: August 26, 2008
Last updated: March 26, 2015
Last verified: March 2015
Results First Received: May 21, 2010  
Study Type: Observational
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Condition: Ovarian Neoplasms
Intervention: Drug: Caelyx (Pegylated Lyposomal Doxorubicin)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Pegylated Lyposomal Doxorubicin 50 mg/m2 every 4 weeks for 6 cycles

Participant Flow:   Overall Study
    Pegylated Lyposomal Doxorubicin
STARTED   224 
COMPLETED   98 
NOT COMPLETED   126 
Toxicity                6 
Tumor progression                56 
Withdrawal by Subject                13 
Death                9 
Reason for discontinuation not specified                29 
No documentation available                13 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pegylated Lyposomal Doxorubicin 50 mg/m2 every 4 weeks for 6 cycles

Baseline Measures
   Pegylated Lyposomal Doxorubicin 
Overall Participants Analyzed 
[Units: Participants]
 224 
Age [1] 
[Units: Years]
Mean (Standard Deviation)
 62.4  (10.95) 
[1] Mean age was calculated for the Intent-to-Treat (ITT) population of 214.
Gender 
[Units: Participants]
 
Female   224 
Male   0 
Region of Enrollment 
[Units: Participants]
 
Austria   224 


  Outcome Measures

1.  Primary:   Occurrences of Infusion Reactions and Palmar-Plantar Erythrodysesthesia (PPE)   [ Time Frame: The observational program was conducted over a period of 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp.
e-mail: ClinicalTrialsDisclosure@merck.com


Publications of Results:

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00743431     History of Changes
Other Study ID Numbers: P04085
Study First Received: August 26, 2008
Results First Received: May 21, 2010
Last Updated: March 26, 2015
Health Authority: Austria: Agency for Health and Food Safety